samedan logo

 
 
spacer
home > white papers > The Importance of ADCC in Assessing Clinically Relevant Differences - Sartorius Stedim BioOutsource Ltd
WHITE PAPERS

Sartorius Stedim BioOutsource Ltd

phone +44 (0)141 946 4222
web http://www.biooutsource.com
email 1 Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, UK

The Importance of ADCC in Assessing Clinically Relevant Differences

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
The Importance of ADCC in Assessing Clinically Relevant Differences
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

ACG Acquires Significant Stake in Mumbai-Based IQGEN-X

3 November 2020 The investment is aimed at augmenting R&D and IP in drug development. The funds infusion will enable IQGEN-X to fast-track research on existing ANDAs and also setup a cGMP pilot facility in addition to the already existing R&D facility.
More info >>


White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>


Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement